Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer’s Disease Trajectory?

Interaction Between Vascular Factors and the APOE ε4 Allele in Predicting Rate of Progression in Alzheimer's Disease

(2018) Michelle M. Mielke et al.   JOURNAL OF ALZHEIMERS DISEASE

Risk Classification in Mild Cognitive Impairment Patients for Developing Alzheimer's Disease

(2018) Bin Zhou et al.   JOURNAL OF ALZHEIMERS DISEASE

Heart Diseases and Long-Term Risk of Dementia and Alzheimer's Disease: A Population-Based CAIDE Study

(2018) Minna Rusanen et al.   JOURNAL OF ALZHEIMERS DISEASE

Neuroinflammation in Alzheimer's disease: Current evidence and future directions

(2016) Valeria Calsolaro et al.   Alzheimers & Dementia

The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study

(2015) Renée FAG de Bruijn et al.   BMC Medicine

Prevalence of Amyloid PET Positivity in Dementia Syndromes

(2015) Rik Ossenkoppele et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Potential for primary prevention of Alzheimer's disease: an analysis of population-based data

(2014) Sam Norton et al.   LANCET NEUROLOGY

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2

(2012) G. S. Collins et al.   BMJ-British Medical Journal

The projected effect of risk factor reduction on Alzheimer's disease prevalence

(2011) Deborah E Barnes et al.   LANCET NEUROLOGY

Coronary risk correlates with cerebral amyloid deposition

(2011) Bruce R. Reed et al.   NEUROBIOLOGY OF AGING

Human apoE Isoforms Differentially Regulate Brain Amyloid-  Peptide Clearance

(2011) J. M. Castellano et al.   Science Translational Medicine

Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans

(2010) Paul S. Aisen et al.   Alzheimers & Dementia

Midlife Smoking, Apolipoprotein E and Risk of Dementia and Alzheimer’s Disease: A Population-Based Cardiovascular Risk Factors, Aging and Dementia Study

(2010) M. Rusanen et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

(2009) Clifford R. Jack et al.   BRAIN

Apolipoprotein E ɛ4 magnifies lifestyle risks for dementia: a population-based study

(2008) Miia Kivipelto et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study

(2008) Chih-Chiang Chiu et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY